Aptorum Group Limited (APM)
- Previous Close
5.0000 - Open
4.9800 - Bid --
- Ask --
- Day's Range
4.9000 - 5.1600 - 52 Week Range
1.3500 - 17.4900 - Volume
8,687 - Avg. Volume
2,492,981 - Market Cap (intraday)
27.301M - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6200 - Earnings Date Apr 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.
www.aptorumgroup.comRecent News: APM
Performance Overview: APM
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APM
Valuation Measures
Market Cap
27.30M
Enterprise Value
28.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
52.30
Price/Book (mrq)
1.10
Enterprise Value/Revenue
7.39
Enterprise Value/EBITDA
-0.62
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.30%
Return on Equity (ttm)
-37.40%
Revenue (ttm)
431.38k
Net Income Avi to Common (ttm)
-2.82M
Diluted EPS (ttm)
-0.6200
Balance Sheet and Cash Flow
Total Cash (mrq)
2.01M
Total Debt/Equity (mrq)
1.46%
Levered Free Cash Flow (ttm)
-3.98M
Research Analysis: APM
Company Insights: APM
APM does not have Company Insights